These priorities are; 1 growth of a diversified global business, 2 delivery of more products which offer more value, 3 simplifying operating model. Gow diversified global business by creating a balanced business and product portfolio capable of delivering sustainable sales growth. Te main business areas are pharmaceuticals, vccines and consumer healthcare which provide the company significant competitive advantages and opportunity of synergy. Dliver products of value: Te Company has re-engineered the research and development (R&D) division in the organisation to develop a whole bunch of products that offer improvement treatment of patients and healthcare providers.
Te company has outsourced the research activities allowing access to new areas of science and share the risk of development of its partners. Parmaceutical companies are making great contribution to the economy of UK, hgher than most other high-tech industries. Te National Health Service (NHS) accounts for more than 98% of UK’s prescribed medicines market, wich is the sixth largest pharmaceutical market in the world. Mst of this market is driven by approximately 35,000 general practitioners (GPs) of UK. Te Pharmaceutical industry of UK an open market, were the leading foreign companies and brands have strong presence.
Wile the growth rate of this market has been decelerating, i remains one of the fastest growing components in NHS expenditure. Te NHS does not generate any kind of national reimbursement list, bt the UK government has adopted several means to keep medicines expenditure under control. Tese include cash incentives and constraints for GPs, ependiture on medicines, idividual quarterly updates on GP prescriptions, te publication of a list of medicines that cannot be prescribed by GPs, switching of some prescription-only medicines to over-the-counter medicines, ad a co-payment system.
Te pharmaceutical industry has generally performed relatively well in the UK market, mnaging to preserve incentives to innovation. Dug makers and governments has increasingly entered into the agreements that provide some form of risk- sharing or price protection for new drugs. Snce most European governments, icluding the UK authorities, ae focussing on cost containment in the healthcare sector, aternative pricing schemes for medicines allow for budget control, a well as providing patients with access to highly innovative Rcently the European...
Please type your essay title, choose your document type, enter your email and we send you essay samples